Does Gateway Health Plan Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is an oral direct Factor Xa inhibitor approved by the FDA for reducing stroke risk in nonvalvular atrial fibrillation, treating and preventing recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and providing post-surgical VTE prophylaxis after hip or knee replacement surgery. The FDA prescribing information confirms all four indications and the dosing ranges used across them.

Why Apixaban Is Prescribed Over Warfarin

Warfarin dominated anticoagulation for decades, but its narrow therapeutic index, frequent INR monitoring, and multiple food-drug interactions created a significant clinical burden. The ARISTOTLE trial (N=18,201) published in the New England Journal of Medicine found that apixaban reduced the rate of stroke or systemic embolism by 21% compared with warfarin (hazard ratio 0.79, 95% CI 0.66 to 0.95, P<0.001), while also producing significantly less major bleeding. That trial is the cornerstone evidence insurers and formulary committees review when deciding whether to cover apixaban at all.

The Cost Problem Driving Coverage Questions

A 30-day supply of brand-name Eliquis retails at approximately $550, $600 without insurance, which is why formulary placement and prior authorization status matter enormously to patients. Generic apixaban (approved by the FDA in 2023) has begun to reduce that retail price, but brand Eliquis remains the product most plan formularies reference in their step-therapy criteria.

How Gateway Health Plan Formularies Work

Gateway Health Plan is a Pennsylvania-based managed-care organization that primarily serves Medicaid and Medicare-Medicaid (dual-eligible) populations. Because it operates as a Medicaid managed-care organization (MCO), its formulary structure follows both federal Medicaid rules and Pennsylvania Department of Human Services requirements.

Formulary Tiers and What They Mean

Medicaid MCO formularies typically arrange drugs into three to five tiers:

• Tier 1: Generic preferred drugs, lowest or zero copay
• Tier 2: Preferred brand drugs, modest copay
• Tier 3: Non-preferred brand drugs, higher copay or prior authorization
• Tier 4/5: Specialty or high-cost drugs, most restrictive access

Eliquis sits on Tier 3 or Tier 4 in most Medicaid managed-care formularies nationally, meaning prior authorization is the default gatekeeping mechanism. The CMS Medicaid Drug Rebate Program rules at 42 CFR §447.512 require that any covered outpatient drug be available with proper authorization, but they do not prevent MCOs from applying utilization management.

Prior Authorization Criteria Gateway Health Typically Applies

While Gateway's exact current formulary document should always be confirmed at the time of prescribing (formularies update quarterly), the prior authorization criteria commonly applied to Eliquis by Medicaid MCOs in Pennsylvania include:

1. A documented diagnosis consistent with an FDA-approved indication (nonvalvular AF, DVT, PE, or post-surgical prophylaxis).
2. A contraindication to warfarin, or evidence of warfarin failure or intolerance, or a documented clinical reason why warfarin monitoring is not feasible.
3. A prescriber attestation that the patient's creatinine clearance is appropriate for the requested dose (the FDA label recommends dose reduction for apixaban in patients meeting two of three criteria: age 80+, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher).

The 2023 American Heart Association/American College of Cardiology AF Guideline gives a Class I recommendation (Level of Evidence A) to non-vitamin K oral anticoagulants (NOACs) like apixaban over warfarin for patients with AF who are NOAC-eligible, which is precisely the language clinicians should quote in prior authorization letters.

Step Therapy: The Warfarin-First Requirement

Step therapy means the insurer requires you to try a less expensive drug before they will approve the requested one. For Eliquis, that typically means a documented trial of warfarin.

When Step Therapy Applies

Step therapy for Eliquis is most commonly triggered when the indication is atrial fibrillation or DVT/PE in a patient who has not previously tried anticoagulation. If a patient is newly diagnosed with AF, Gateway Health's utilization management vendor may require documentation of at least 30 to 90 days of warfarin therapy before Eliquis is approved, unless the prescriber demonstrates a specific contraindication.

Exceptions That Bypass Step Therapy

Federal regulations and Pennsylvania Medicaid policy create several recognized exceptions to step therapy requirements. These include:

• Prior treatment failure on warfarin (e.g., documented time-in-therapeutic range below 60% despite adequate monitoring, which a 2016 JAMA Internal Medicine analysis identified as the threshold below which warfarin's net clinical benefit becomes questionable).
• An adverse reaction or allergy to warfarin.
• A documented clinical situation where INR monitoring is not feasible (e.g., geographic isolation, cognitive impairment without caregiver support).
• Post-surgical VTE prophylaxis after hip or knee replacement, where clinical guidelines do not support warfarin as the primary agent in the same way.

Physicians should write these exceptions explicitly into the prior authorization request rather than assuming the reviewer will infer them.

How to Request Prior Authorization for Eliquis Through Gateway Health

The prior authorization process begins with the prescribing physician, not the patient. Here is the sequence that produces the highest approval rate.

Step 1: Confirm Current Formulary Status

Call Gateway Health Plan member services (the number is on the back of the member's insurance card) or access the online formulary lookup tool at Gateway's provider portal. Formulary status changes on January 1, April 1, July 1, and October 1 each year, so confirming at the point of prescribing is essential.

Step 2: Submit a Complete PA Request

A complete prior authorization package for Eliquis typically includes:

• The PA request form (Gateway's specific form, available through their provider portal).
• The relevant ICD-10 diagnosis code (e.g., I48.0, I48.20 for various AF subtypes; I82.401 for DVT).
• Recent clinical notes documenting the indication, relevant lab values (serum creatinine, weight), and any warfarin history.
• A letter of medical necessity citing the AHA/ACC or American College of Chest Physicians 2022 VTE guidelines as applicable.

Step 3: Follow Up Within 72 Hours

Pennsylvania Medicaid rules require urgent PA decisions within 72 hours and standard decisions within 14 calendar days. If no response is received, the prescriber's office should call the PA department directly. Delays in the PA process are not approvals.

What Happens If Coverage Is Denied?

A denial is not the end of the road. Medicaid managed-care denials are subject to both internal appeals and state fair hearing rights under 42 CFR §438.400 to 438.424.

Internal Appeal

File the internal appeal within 60 days of the denial notice. Attach updated clinical documentation, any relevant peer-reviewed literature (the ARISTOTLE data cited above is appropriate), and a letter from the treating cardiologist or hematologist if possible. Roughly 40 to 60% of pharmacy appeals succeed when full clinical documentation accompanies the request, according to CMS data on Medicaid managed-care grievances and appeals.

State Fair Hearing

If the internal appeal fails, Pennsylvania Medicaid members have the right to request a state fair hearing through the Pennsylvania Department of Human Services. Requesting a hearing within 10 days of the denial notice allows the member to continue receiving the disputed medication at no cost while the hearing is pending, a process called "aid paid pending."

Peer-to-Peer Review

Before filing a formal appeal, ask for a peer-to-peer review call between the treating physician and the plan's medical reviewer. This call takes 15 to 20 minutes and overturns a meaningful proportion of initial denials, particularly when the prescribing physician can articulate why warfarin is contraindicated or has already failed.

Eliquis Copay Assistance and Patient Support Programs

Manufacturer copay assistance through Bristol-Myers Squibb and Pfizer's Eliquis 360 Support program can reduce out-of-pocket cost to as low as $10 per month for eligible commercially insured patients. The critical restriction: this program is explicitly not available to patients whose primary coverage is a government program, including Medicaid, Medicare Part D, or any other federal or state healthcare program. This restriction exists because the federal Anti-Kickback Statute prohibits manufacturer assistance that reduces a federal beneficiary's cost-sharing obligations.

Generic Apixaban as a Cost-Saving Alternative

The FDA approved generic apixaban in 2023, and several manufacturers now market it. Because generics are typically placed on Tier 1 or Tier 2 of Medicaid formularies, generic apixaban may face less restrictive prior authorization criteria than brand Eliquis. The FDA Orange Book listing for apixaban confirms therapeutic equivalence ratings. Prescribers should confirm with Gateway Health whether substituting generic apixaban on the PA request changes the approval threshold.

Pennsylvania Pharmaceutical Assistance Programs

Pennsylvania's PACE and PACENET programs provide prescription assistance for older adults who do not qualify for Medicaid. The Pennsylvania PACE program sets income eligibility thresholds and copay structures that may make Eliquis more affordable for near-Medicaid patients. A social worker or patient navigator at the prescribing practice can support enrollment.

Clinical Indications Where Coverage Is Most Likely Approved

Not all Eliquis indications face the same coverage hurdles. Understanding where Gateway Health and similar Medicaid MCOs draw their coverage lines can help prescribers frame their PA requests strategically.

Nonvalvular Atrial Fibrillation

This is both the most common indication and the one with the strongest evidence base. The ARISTOTLE trial result cited above, combined with the Class I AHA/ACC guideline recommendation, gives prescribers a strong clinical narrative. The PA request should explicitly state that the patient has nonvalvular AF (as opposed to AF with a mechanical heart valve, where warfarin remains the standard of care per FDA label language) and that a NOAC is guideline-recommended.

DVT and PE Treatment

The AMPLIFY trial (N=5,395), published in the New England Journal of Medicine, demonstrated that apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for acute DVT/PE treatment, with a statistically significant 69% reduction in major bleeding (hazard ratio 0.31, 95% CI 0.17 to 0.55, P<0.001). That bleeding advantage is the clinical argument that most directly justifies choosing apixaban over warfarin for DVT/PE, and it should anchor any PA letter for this indication.

Post-Surgical VTE Prophylaxis

Hip and knee replacement patients have an FDA-approved indication for apixaban 2.5 mg twice daily for 12 days (knee) or 35 days (hip). For this short-duration indication, step-therapy requirements are less commonly applied because the brief treatment window makes a warfarin trial impractical. Formulary exceptions for surgical prophylaxis are worth requesting explicitly.

Extended DVT/PE Prevention

The AMPLIFY-EXT trial (N=2,486) showed that extended apixaban therapy (both 2.5 mg and 5 mg twice daily) reduced recurrent VTE by approximately 80% compared with placebo without a significant increase in major bleeding (see NEJM publication). Extended prevention is an indication where coverage may require additional documentation of ongoing VTE risk factors, such as active cancer, antiphospholipid syndrome, or prior recurrence.

Documenting Medical Necessity: What Prescribers Must Include

A prior authorization denial often traces back to an incomplete initial submission rather than a genuine formulary exclusion. The documentation that most reliably supports approval includes:

• The specific ICD-10 code and clinical notes confirming the diagnosis.
• Lab values dated within 90 days: serum creatinine, weight, and (for AF) CHA2DS2-VASc score. The 2023 AHA/ACC AF guideline recommends anticoagulation for men with CHA2DS2-VASc score of 2 or higher and women with score of 3 or higher.
• A clear statement about warfarin suitability: either a documented contraindication, a prior adverse event, or a history of poor INR control (time-in-therapeutic range below 65%).
• Reference to the specific clinical trial or guideline that supports the prescribing decision. Peer reviewers respond to named evidence.

Prescribers who submit all of this in the initial request reduce the probability of a denial requiring appeal and shorten the time before the patient can fill their prescription.

Monitoring Requirements Once Coverage Is Approved

Unlike warfarin, apixaban does not require routine coagulation monitoring, which is one of its main practical advantages. The FDA prescribing information specifies no routine INR or anti-Xa level testing for patients on apixaban. However, Gateway Health Plan's authorization may require periodic renewal, typically every 12 months for chronic indications like AF, with updated clinical notes confirming the diagnosis is ongoing and the dose remains appropriate.

Renal function should be checked at least annually in patients with baseline CKD, since apixaban dose reduction criteria depend on serum creatinine. Patients with creatinine clearance below 15 mL/min were excluded from the major trials, and the FDA label notes limited data in end-stage renal disease, so Gateway Health may request documented renal function before renewing the PA in this population.